Tango and Erasca Begin Phase 1/2 Vopimetostat Combination Study
The study is evaluating vopimetostat with ERAS-0015 in patients with MTAP-deleted pancreatic cancer and MTAP-deleted, RAS-mutant non-small cell lung cancer.
The study is evaluating vopimetostat with ERAS-0015 in patients with MTAP-deleted pancreatic cancer and MTAP-deleted, RAS-mutant non-small cell lung cancer.